Total med-tech financing through the first half (H1) of 2026 reached $12.66 billion, down from 2025’s $17.56 billion but in line with 2024’s $13.94 billion over the same period.

New drug approvals, financings and deals were seen across the Asia-Pacific biotech sector this week, with China’s National Medical Products Administration (NMPA) granting clearances to Takeda Pharmaceutical Co. Ltd.’s oral orexin receptor 2 agonist oveporexton for narcolepsy, as well as Haisco Pharmaceutical Group’s ciprocopan (HSK-39297) for paroxysmal nocturnal hemoglobinuria.

New drug approvals, financings and deals were seen across the Asia-Pacific biotech sector this week, with China’s National Medical Products Administration (NMPA) granting clearances to Takeda Pharmaceutical Co. Ltd.’s oral orexin receptor 2 agonist oveporexton for narcolepsy, as well as Haisco Pharmaceutical Group’s ciprocopan (HSK-39297) for paroxysmal nocturnal hemoglobinuria.

Continuing the year’s strong IPO activity, Scribe Therapeutics Inc. priced an upsized offering at the high end of its price range, offering 8.6 million shares at $15 apiece for gross proceeds of about $129 million. The company, which is developing CRISPR-based therapies targeting cardiovascular and metabolic diseases, began trading on Nasdaq under the ticker SCTX, with shares getting a warm welcome, opening at $25 and ending the day at $21.65, up 44.3%.

Total med-tech financing through the first half (H1) of 2026 reached $12.66 billion, down from 2025’s $17.56 billion but in line with 2024’s $13.94 billion over the same period.

Axiom Biosciences, rebranded from Cytonus Therapeutics Inc. in June 2026, plans to be one of the first U.S. biotechs to IPO on the main board of The Stock Exchange of Hong Kong. The San Diego-based company is preparing audits as the first step to a potential IPO in 2027.

Biopharma financing activity through the first two quarters of 2026 totaled $60.14 billion, the strongest first-half (H1) showing since 2024’s $70.32 billion and well above 2025’s $29.53 billion over the same period. The second quarter (Q2) of 2026 was particularly strong at $34.69 billion, the highest single quarter since Q1 2024’s $47.25 billion. Q1 came in at $25.45 billion, more than double 2025’s Q1 figure of $13.12 billion.

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that can demonstrate clinical differentiation, strong management teams and a clear path to commercialization.

U.K. biotech has recorded the strongest quarter for venture capital raised in five years, with companies attracting £2.05 billion (US$3.36 billion) in the second quarter (Q2) of 2026. While that figure is dominated by the £1.56 billion series B round raised by Google Deepmind’s AI drug discovery spin-off Isomorphic Labs Ltd, the remaining £498 million is a significant increase to the £279 million raised in Q2 of 2025.

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that can demonstrate clinical differentiation, strong management teams and a clear path to commercialization.